BioSpace News Archive

Case Study highlights how a Medicaid Plan now receives rebates from Biogen for patients who discontinued their treatment with Avonex® (interferon beta-1a) and Tecfidera® (dimethyl fumarate)

Hubbell Lighting, a world leader in lighting innovation, announced today it has launched a series of ultraviolet (“UVC”) germicidal lighting solutions for the commercial lighting marketplace.

InterVenn has announced a collaboration with Agilent Technologies, a leading provider of bio-analytical and scientific instrumentation.

Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present positive results from a Phase 2b study evaluating the efficacy and safety of its investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) in adult patients with moderate-to-severe chronic hand eczema (CHE) in a late-breaking news session at the EADV Virtual Congress

Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (TSX: NEPT) (NASDAQ: NEPT), today announced it has entered into definitive agreements with certain US healthcare focused institutional investors for a private placement of 16,203,700 common shares

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020.

Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the closing of its initial public offering of 6,325,000 shares of its common stock at a price to the public of $16.00 per share

Arena Pharmaceuticals, Inc. announced that on October 15, 2020, the Compensation Committee of its Board of Directors granted to seven new employees inducement stock options to purchase an aggregate of 66,475 shares of its common stock and 11,760 inducement restricted stock units.

Medifast, Inc. (NYSE: MED), the company behind one of the fastest-growing health and wellness communities, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2020 on Monday, November 2, 2020, after market close.

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it was granted Fast Track designation by the Food and Drug Administration (FDA) for the investigation of XP-0863 (diazepam non-aqueous injection) for the treatment of acute repetitive seizures.